-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ELI-002 in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ELI-002 in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ELI-002 in Pancreatic Ductal Adenocarcinoma Drug Details: ELI-002 (VED-002) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ELI-002 in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ELI-002 in Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ELI-002 in Colorectal Cancer Drug Details: ELI-002 (VED-002) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ELI-002 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ELI-002 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ELI-002 in Solid Tumor Drug Details: ELI-002 (VED-002) is under development...
-
Product Insights
Hepatic Injury – Drugs In Development, 2023
Global Markets Direct’s, ‘Hepatic Injury - Drugs In Development, 2023’, provides an overview of the Hepatic Injury pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hepatic Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ensartinib Hydrochloride in Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ensartinib Hydrochloride in Non-Small Cell Lung Cancer Drug Details: Ensartinib hydrochloride (Bemena) is an anti-neoplastic...
-
Product Insights
Acute Spinal Cord Injury – Drugs In Development, 2023
Global Markets Direct’s, ‘Acute Spinal Cord Injury - Drugs In Development, 2023’, provides an overview of the Acute Spinal Cord Injury pipeline landscape. The report provides comprehensive information on the therapeutics under development for Acute Spinal Cord Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Polycystic Kidney Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Polycystic Kidney Disease - Drugs In Development, 2023’, provides an overview of the Polycystic Kidney Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Polycystic Kidney Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Pancreatic Diseases – Drugs In Development, 2023
Global Markets Direct’s, ‘Pancreatic Diseases - Drugs In Development, 2023’, provides an overview of the Pancreatic Diseases pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pancreatic Diseases, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Kidney Fibrosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Kidney Fibrosis - Drugs In Development, 2023’, provides an overview of the Kidney Fibrosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Kidney Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Gastrointestinal Tumor – Drugs In Development, 2023
Global Markets Direct’s, ‘Gastrointestinal Tumor - Drugs In Development, 2023’, provides an overview of the Gastrointestinal Tumor pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gastrointestinal Tumor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...